Nanosonics receives US FDA clearance for next-generation disinfection technology

Infection prevention company Nanosonics has received US Food and Drug Administration clearance for its latest trophon innovation, enabling the commercial launch of trophon3 and trophon2 Plus in the United States, according to an announcement on Tuesday.

The new trophon3 technology delivers over 40 per cent faster cycle times compared to previous generations whilst maintaining the highest clinical efficacy standards for patient safety. The system features expanded digital integration capabilities and offers the broadest traceability capabilities in the ultrasound reprocessing market.

Chief executive Michael Kavanagh said the FDA clearance represents important milestones for the company. “These innovations set a new benchmark in automated high-level disinfection and unlock significant growth opportunity through both new installed base and upgrades,” Kavanagh said on Tuesday.

The trophon3 is expected to drive further penetration into hospital and private physician markets, representing approximately 30,000 new device opportunities in the US. The launch also creates significant global upgrade opportunities, with around 10,000 first-generation trophon EPR devices eligible for upgrade to trophon3.

Additionally, trophon2 Plus offers a software upgrade package for existing trophon2 users, targeting approximately 20,000 devices globally. The technology includes new digital traceability through customers' DICOM imaging database systems and can be customised to suit various customer workflows whilst delivering consistent, reliable disinfection in an environmentally friendly manner.

Picture: LinkedIn